compound 2-13-1 [PMID: 24900824]   Click here for help

GtoPdb Ligand ID: 8112

Compound class: Synthetic organic
Comment: This BUB1 (BUB1 mitotic checkpoint serine/threonine kinase) inhibitor compound was developed as a potential antineoplastic and was granted patent protection in 2013 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 163.36
Molecular weight 551.18
XLogP 2.08
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NC(=O)c1cnccc1Nc1nc(ncc1OCCS(=O)(=O)C)c1nn(c2c1CCC2)Cc1ccccc1F
Isomeric SMILES NC(=O)c1cnccc1Nc1nc(ncc1OCCS(=O)(=O)C)c1nn(c2c1CCC2)Cc1ccccc1F
InChI InChI=1S/C26H26FN7O4S/c1-39(36,37)12-11-38-22-14-30-26(32-25(22)31-20-9-10-29-13-18(20)24(28)35)23-17-6-4-8-21(17)34(33-23)15-16-5-2-3-7-19(16)27/h2-3,5,7,9-10,13-14H,4,6,8,11-12,15H2,1H3,(H2,28,35)(H,29,30,31,32)
InChI Key FFVPQWXBEUUBMF-UHFFFAOYSA-N
References
1. Brazeau JF, Rosse G. (2014)
Novel cycloalkenepyrazoles as inhibitors of bub1 kinase.
ACS Med Chem Lett, 5 (4): 280-1. [PMID:24900824]
2. Hitchcock M, Hilger C-S, Mengel A, Briem H, Holton S, P¨:tter V, Siemeister G, Prechtl S, FERNÁNDEZ-MONTALVÁN AE, Stegmann C. (2013)
Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer.
Patent number: WO2013167698. Assignee: Bayer Pharma Aktiengesellschaft. Priority date: 11/05/2012. Publication date: 14/11/2013.